MagVenture Webinar: Clinical Application of rTMS for Depression

Understanding rTMS for Treatment-Resistant Depression. Repetitive Transcranial Magnetic Stimulation (rTMS) is a modern, non-invasive neurostimulation procedure widely utilized in the treatment of various neuropsychiatric disorders, particularly treatment-resistant depression. Webinar Overview. Hosted by Sebastian Lyschik (National Sales Manager) and featuring expert guest speaker Prof. Dr. med. Michael Landgrebe, this comprehensive session is designed to bridge the gap between neurophysiological theory and daily clinical practice. The presentation covers three core areas:. Neurophysiological Foundations: An introduction to how targeted magnetic pulses influence specific brain areas and modulate complex neural networks., Scientific Evidence: A critical overview of the current study landscape, exploring clinical efficacy, limitations, side effects, and official guideline recommendations across different clinical pictures., Practical Clinical Application: Actionable, hands-on guidance covering patient selection, device settings, safety protocols, and effective therapy planning. Featured Speaker Prof. Dr. med. Michael Landgrebe – Medical Director of kbo Lech-Mangfall-Kliniken gGmbH and Chief Physician of kbo-Lech-Mangfall-Klinik Agatharied. (Note: This presentation is intended for professionals in medicine, healthcare, and research.). Regulatory Disclaimer. The views and opinions expressed in this webinar do not necessarily reflect the official policy or position of MagVenture or its affiliates. MagVenture TMS Therapy® is CE-certified for the "treatment of Major Depressive Disorder in adult patients who have failed to achieve satisfactory improvement from two prior antidepressant medications, at or above the minimal effective dose and duration in the current episode." For patients who respond to the treatment of Major Depressive Disorder and exhibit symptoms of comorbid anxiety disorders, the clinical benefit may also include a reduction in anxiety symptoms.